The worldwide elderly population is expected to grow by an additional 694 million people by
2025. By that time, there will be approximately two billion elderly people in the world, most of …

The success of antiretroviral therapy in treating HIV infection has greatly prolonged life
expectancy in affected individuals, transforming the disease into a chronic condition. A …

Background Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss
compared with abacavir/lamivudine (ABC-3TC) in a randomized simplification trial (STEAL …

Background Osteopenia, osteoporosis, and low bone mineral density are frequent in
patients with HIV. We assessed the 96 week loss of bone mineral density associated with a …

Context and Objective: The objective of the study was to assess the effects of HIV infection
and antiretroviral therapy on change in bone mineral density (BMD) in postmenopausal …

Background Human immunodeficiency virus (HIV) and combination antiretroviral therapy
(cART) may both contribute to the higher prevalence of osteoporosis and osteopenia in HIV …

HIV‐infected patients receiving antiretroviral therapy present an increased prevalence of
age‐related comorbidities, including osteoporosis. HIV protease inhibitors (PI s) have been …

Both HIV infection and antiretroviral therapy (ART) are associated with lower bone mineral
density (BMD) and increased fracture risk. Because the relative contributions of ART and …

The population of people living with HIV (PLWH) is growing older with an estimated 4 million
over the age of 50 years, a figure which has doubled since the introduction of effective …

Objective: Antiretroviral therapy (ART) has been implicated in bone loss in HIV. The role of
inflammation and vitamin D is unclear and better investigated in ART-naive individuals …